Granlibakken Tahoe Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2007



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Molecular Mechanisms of Fibrosis: From Bench to Bedside (C5)


Organizer(s) Thomas A. Wynn, W. Michael Gallatin and Mark Lupher, Jr.
March 11—15, 2007
Granlibakken Tahoe • Tahoe City, California USA
Abstract Deadline: Nov 13, 2006
Late Abstract Deadline: Dec 12, 2006
Scholarship Deadline: Nov 13, 2006
Early Registration Deadline: Jan 11, 2007

Sponsored by ICOS Corporation

Summary of Meeting:
Tissue fibrosis or scarring is a leading cause of morbidity and mortality worldwide. Current health statistics suggest that almost 45% of all deaths in the western world are attributed to some type of chronic fibrotic disease. Fibrosis affects nearly all tissues and organ systems. Diseases in which fibrosis is a major cause of morbidity and mortality include the interstitial lung diseases, liver cirrhosis, kidney disease, heart disease, systemic sclerosis, among others. Fibrotic tissue remodeling can also influence cancer metastasis and accelerate chronic graft rejection in transplant recipients. Current treatments for fibrotic disorders target the inflammatory cascade, but they have been largely unsuccessful, primarily because the mechanisms that are involved in fibrogenesis are believed to be distinct from those involved in inflammation. Because mechanistic studies are difficult to carry out in humans, numerous experimental models have been developed over the past few years to dissect the immunological and molecular mechanisms of fibrosis. The first of new therapies based on these models is just beginning to approach clinical testing. The goal of this meeting is to bring together academic researchers, clinicians, and members of the pharmaceutical industry to discuss the most recent advances in the field and to identify common mechanistic themes of tissue fibrogenesis in various tissue systems. By bringing together a diverse group of researchers, the meeting will provide a more integrated perspective from basic disease mechanisms through to the more pragmatic challenges of clinical trial design in chronic progressive disease. Some of the topics that will be discussed include: extracellular matrix remodeling in fibrosis and cancer; the role of bone marrow in epithelial-mesenchymal transitions; experimental models of fibrosis; pulmonary, cardiac, liver, and kidney fibrosis; systemic sclerosis (scleroderma); as well as recent clinical developments with experimental anti-fibrotic drugs. This meeting will feature plenary talks from key investigators in the field and will also include workshops and poster sessions.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, MARCH 11

15:00—19:30
Registration

Prefunction
19:30—19:45
Opening Remarks

Mountain/Lake Rooms
Thomas A. Wynn, Pfizer, USA

19:45—20:45
Overview of Fibrosis: Mechanisms and Treatment
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake Rooms
Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA
Fibrogenic Cells in Tissue Repair - Sources, Features and Implications


MONDAY, MARCH 12

07:00—08:00
Breakfast

Granhall
08:00—11:15
The Extracellular Matrix
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake Rooms
* W. Michael Gallatin, Frazier Healthcare Ventures, USA

Mark L. Lupher, Jr., Muregen, LLC, USA
Identification and Characterization of Small Molecule VLA-1 Inhibitors as Potential Therapy for Inflammatory and Fibrotic Disease

David A. Brenner, University of California, San Diego, USA
Regulation of Hepatic Inflammation and Fibrogenesis

Raghu Kalluri, University of Texas MD Anderson Cancer Center, USA
EMT in Organ Fibrosis

Gary W. Hunninghake, University of Iowa College of Medicine, USA
Genetic and Environmental Factors Influencing Pulmonary Fibrosis – Biomarkers

Andrew Leask, University of Western Ontario, Canada
Short Talk: Protein Kinase C Epsilon is Required for Cutaneous Wound Closure and Myofibroblast Formation and Function

Yana G. Kamberov, Harvard School of Dental Medicine, USA
Short Talk: Halofuginone is a Small Molecule Regulator of a Novel Transcriptional Complex that Controls Extracellular Matrix Gene Expression

09:20—09:40
Coffee Break

Prefunction
11:15—13:00
Poster Setup

Bay Room
13:00—22:00
Poster Viewing

Bay Room
14:30—16:30
Workshop 1: Experimental Models of Fibrosis

Mountain/Lake Rooms
* Michael P. Keane, University of California, Los Angeles, USA

* Sergei P. Atamas, University of Maryland School of Medicine, USA
Paradoxical Regulation of Pulmonary Fibrosis by T Lymphocytes

Amir Mohsenin, University of Texas Health Science Center - Houston, USA
Angiogenesis Resulting from Adenosine Mediated Lung Injury

Virender K. Rehan, Harbor University of California, Los Angeles Medical Center, USA
A Novel Approach to Prevent and/or Treat Chronic Lung Disease

Qihe Xu, King's College London School of Medicine, UK
In Vitro Models of TGF-beta-Induced Fibrosis Suitable for High-Throughput Screening of Anti-fibrotic Agents

Annie Pardo, Universidad Nacional Autonoma de Mexico, Mexico
Bleomycin Induced Pulmonary Fibrosis is Attenuated in Transgenic Mice Overexpressing MMP9. Role of Insulin Growth Factor Binding Protein 3 (IGFBP3)

Jaspreet Pannu, Medical University of South Carolina, USA
Smad1 is a Critical Regulator of the TGF-beta-Mediated Fibrogenic Response via Induction of CTGF/CCN2 Gene Independently of Smad2/3 Activation

Marie-Catherine Vozenin-Brotons, IRSN/IGR, France
Reversal of Radiation-Induced Intestinal Fibrosis by Pravastatin Involves Rho/CCN2 Inhibition in Rats and Human Samples

Andrew M. Tager, Massachusetts General Hospital, USA
The Lysophosphatidic Acid Receptor LPA1 Regulates Pulmonary Fibrosis Following Lung Injury by Mediating Fibroblast Recruitment and Vascular Leak

Lisa R. Young, Cincinnati Children's Hospital Medical Center, USA
Susceptibility of Hermansky-Pudlak Mice to Early Alveolar Type II Cell Apoptosis and Bleomycin-Induced Pulmonary Fibrosis

16:30—17:00
Coffee Available

Prefunction
17:00—19:00
Origins of Myofibroblasts
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake Rooms
* Robert M. Strieter, University of Virginia School of Medicine, USA

Mark L. Entman, Baylor College of Medicine, USA
Bone Marrow-Derived Fibroblast Precursors Mediate Ischemic Cardiomyopathy in Mice

Eric Neilson, Vanderbilt University School of Medicine, USA
Epithelial-Mesenchymal Transitions (EMT) in Renal Fibrosis

Sem H. Phan, University of Michigan Medical School, USA
Role of Bone Marrow–Derived Progenitor Cells in Pulmonary Fibrosis

Moises Selman, Instituto Nacional de Enfermedades Respiratorias, Mexico
Short Talk: Circulating Fibrocytes: A Potential Source of Fibroblasts/Myofibroblasts in Idiopathic Pulmonary Fibrosis

19:00—20:00
Dinner

Granhall
19:30—22:00
Poster Session 1

Bay Room
20:00—21:00
Social Hour

Bay Room

TUESDAY, MARCH 13

07:00—08:00
Breakfast

Granhall
08:00—11:15
Pulmonary Fibrosis
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake Rooms
* Cory M. Hogaboam, Cedars-Sinai Medical Center, USA

Dean Sheppard, University of California, San Francisco, USA
Integrin ávâ6-Mediated TGFâ Activation in Tissue Fibrosis

Jack Gauldie, McMaster University, Canada
TGFbeta1 and Smad3 link inflammation to progressive fibrosis

Heather F. Lakatos, University of Rochester, USA
Short Talk: Triterpenoids and Other PPAR Gamma Ligands have Potent Anti-Fibrotic Activity

Robert M. Strieter, University of Virginia School of Medicine, USA
CXC Chemokines in Mediating Vascular Remodeling and Trafficking of Adult Progenitor Cells in Pulmonary Fibrosis

Jack A. Elias, Yale School of Medicine, USA
Transgenic Modeling of TGF-beta in the Murine Lung

Richard H. Gomer, Texas A&M University, USA
Short Talk: Inhibition of Bleomycin-induced Pulmonary Fibrosis by Serum Amyloid P

09:20—09:40
Coffee Break

Prefunction
11:15—13:00
Poster Setup

Bay Room
13:00—22:00
Poster Viewing

Bay Room
14:30—16:30
Workshop 2: Mechanisms and Novel Treatment Strategies

Mountain/Lake Rooms
* Annie Pardo, Universidad Nacional Autonoma de Mexico, Mexico

April Stempien-Otero, University of Washington, USA
The Role of Arginase in Urokinase Plasminogen Activator Induced Cardiac Fibrosis

Shizuya Saika†, Wakayama Medical University, Japan
Loss of Osteopontin Attenuates Tissue Fibrosis in Injured Eye Tissues in Mice: Suppression of Smad Signal, Epithelial-Mesenchymal Transition and Fibroblast Activation

Debra F. Higgins, University of Pennsylvania, USA
Hypoxic Signaling Through HIF-1 Enhances Renal Fibrosis

Harm Peters, Charité, Campus Mitte, Germany
Targeting TGF-ß Overexpression in Renal Fibrosis: Rosuvastatin is Additive to High Dose Candesartan

Frank Eitner, Aachen University, Germany
PDGF-C Acts as a Potent Pro-Inflammatory Cytokine that Mediates Renal Interstitial Fibrosis in vivo

Alison Crawford MacKinnon, University of Edinburgh, Scotland
Regulation of Alternative Macrophage Activation by Galectin-3 Controls Renal Fibrosis Following Ureteric Obstruction

Melanie Königshoff, University of Giessen Lung Center, Germany
Wnt-Inducible Signalling Protein (WISP)-1: A Novel Regulator of Idiopathic Pulmonary Fibrosis Amenable to Therapeutic Intervention

Patricia Fernandez, New York University, USA
Elevations in Tissue Adenosine Levels Promote Dermal Fibrotic Features and IL-13 Production

* David John Abraham, University College, UK
Platelet-Derived Growth Factor Receptor Beta is Essential for Mesenchymal Cell Activation, Recruitment and Differentiation in Wound Healing and Tissue Fibrosis

16:30—17:00
Coffee Available

Prefunction
17:00—19:00
Fibrosis as a Consequence of Chronic Exposure to Pathogens
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake Rooms
* Mark L. Lupher, Jr., Muregen, LLC, USA

Thomas A. Wynn, Pfizer, USA
The Role of TH2 Cytokines and Their Receptors in Fibrogenesis

Barbara A. Burleigh, Harvard School of Public Health, USA
Modulation of Connective Tissue Growth Factor Expression by an Intracellular Pathogen: A Potential Tool for Probing the Fibrogenic Pathway?

Ana L. Mora, University of Pittsburgh, USA
Short Talk: Gammaherpesvirus-Induced Pulmonary Fibrosis in Mice Defective of IFN-Gamma Signaling

Cory M. Hogaboam, Cedars-Sinai Medical Center, USA
Chemokines: Protein Programmers of the Peribronchial Fibrotic Response in Chronic Fungal Asthma

19:00—20:00
Dinner

Granhall
19:30—22:00
Poster Session 2

Bay Room
20:00—21:00
Social Hour

Bay Room

WEDNESDAY, MARCH 14

07:00—08:00
Breakfast

Granhall
08:00—11:00
Clinical Developments
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake Rooms
* Michael Gilman, Padlock Therapeutics, USA

Shelia M. Violette, Admirx Inc., USA
Short Talk: Integrin Alphavbeta6 Monoclonal Antibodies: Potential Therapeutics for Fibrotic Indications

David Y. Liu, Trenovus Inc., USA
Anti-CTGF (CCN2) Human Antibody Therapy, FG-3019, Prevents and Reverses Renal and Cardiovascular Pathologies in Animal Models of Diabetic Complications

John Varga, Feinberg School of Medicine, USA
Pathogenesis and Antifibrotic therapies in Scleroderma/systemic sclerosis

Scott M. Lonning, Cell Signaling Technology, USA
Clinical Trials with Monoclonal Antibodies Against TGF-beta in the Treatment of Fibrotic Diseases

James S. Swaney, Inception Sciences, USA
Short Talk: An Emerging Role of Sphingosine-1-Phosphate in Tissue Fibrosis: Therapeutic Potential of an Anti-S1P Monoclonal Antibody

Elen S. Rosler, Myelin Repair Foundatoin, USA
Short Talk: Phenotypic Screening for Novel Anti-Fibrotic Drugs Using BioMAP® Systems

09:20—09:40
Coffee Break

Prefunction
16:30—17:00
Coffee Available

Prefunction
17:00—19:15
Liver Fibrogenesis
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake Rooms
* Thomas A. Wynn, Pfizer, USA

Axel M. Gressner, Klinikum Rwth-Aachen, Germany
TGF-beta and the Smad-Pathway in Experimental Liver Fibrogenesis

Don C. Rockey, University of Texas Southwestern Medical Center, USA
Role of Endothelins in Liver Fibrosis

Stefano Fiorucci, Universita degli Studi di Perugia, Italy
FXR and Liver Fibrosis

Steven Dooley, Medical Faculty Mannheim, University of Heidelberg, Germany
Short Talk: TGF-beta and Hepatocyte Transdifferentiation in Liver Fibrogenesis

Jonathan A. Dranoff, Yale University School of Medicine, USA
Short Talk: Epithelial-Mesenchymal Interactions in Biliary Cirrhosis

19:15—20:15
Social Hour

Bay Room
20:15—21:15
Dinner

Granhall
20:00—23:00
Entertainment

Granhall

THURSDAY, MARCH 15

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13HL087522-01




We gratefully acknowledge additional support for this conference from:

ICOS Corporation

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Genzyme Corporation


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676